Haleon Pakistan Delivers Strong Growth in First Nine Months of FY 2025
Haleon Pakistan Ltd. reported a solid performance in the first nine months of FY 2025, supported by strong brand demand, price increases, and better margins. In its analyst briefing, the company shared key updates on financial performance, product strategy, and upcoming expansion plans.
Strong Financial Performance
The company’s profit rose sharply, increasing 439% year-on-year to PKR 4.6 billion (EPS: PKR 39.2). This improvement came from:
-
Higher sales volumes
-
Price adjustments
-
Stronger gross margins, which increased to 38.4% from 33.3%
Revenue reached PKR 32.2 billion, up 17% YoY, driven by a combination of price increases and a 7% rise in volumes.
Key Brands Drive Growth
Around 80% of Haleon’s sales came from three major brands:
-
Panadol (49% of total revenue)
-
Cac-1000 (22%)
-
Sensodyne (leading oral care brand)
Panadol remains the largest contributor, with 75% of its portfolio classified as essential, ensuring consistent demand.
API sourcing is 60% imported and 40% local.
Segment Performance
-
FMCG segment grew 32%
-
OTC segment grew 18%
The company plans to increase its focus on oral care, which is already expanding faster than overall company growth.
New Products & Pipeline
During FY 2025 so far, Haleon launched:
-
Centrum
-
Panadol Ultra
-
New oral care variants
The response has been strong. The company also plans to introduce two new Panadol variants:
-
Panadol Migraine
-
Panadol Menstrual
Capacity Expansion
The Jamshoro plant expansion is expected to be completed in the second half of FY 2026.
After expansion:
-
Panadol tablet capacity will rise from 30 million to 50 million tablets per day
-
Liquid production will increase from 52 million to 57 million bottles per day
-
Outsourced Panadol production will drop from 36% to just 4%
Haleon also noted that 99% of its products are now made locally, supported by localized packaging material—important for the national track-and-trace system.
Export Plans
The company is actively working to increase exports, particularly to markets in:
-
Southeast Asia
-
Africa
Export certification usually takes one to two years, but margins in these markets are attractive.
Haleon also confirmed that it is not affected by recent Afghanistan border disruptions, as it does not supply that market.
Key Challenge
The company highlighted ongoing pressure from Pakistan’s low-price threshold mechanism, which affects the pricing of low-priced medicines.
Outlook
Management aims to sustain the sales momentum seen in the first nine months of FY 2025. With new product launches, higher production capacity, and export expansion, the company expects continued growth into FY 2026.
https://dps.psx.com.pk/download/document/264338.pdf
